# Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

Source: https://onco.cc/trials/nct07252232/  
OnCo record `nct07252232` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Daraxonrasib in pancreatic ductal adenocarcinoma, run by Revolution Medicines, Inc., now recruiting.

## Summary

Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC) is a phase 3 interventional study registered as NCT07252232 by Revolution Medicines, Inc., with 500 participants planned, started 2025-12-15 and due to reach its primary completion in 2029-05-10. Interventions recorded: daraxonrasib. Conditions listed: Pancreatic Cancer, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma (PDAC). No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07252232
- Phase: 3
- Setting: RASolute 304: A Phase 3 Multicenter, Open-label, Randomized, 2-Arm Study of Adjuvant Daraxonrasib Versus Standard of Care Observation Following Completion of Neoadjuvant and/or Adjuvant Chemotherapy in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
- Sponsor: Revolution Medicines, Inc.
- Enrolled: 500

## Sources

- ClinicalTrials.gov NCT07252232: https://clinicaltrials.gov/study/NCT07252232

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- drugs: [Daraxonrasib](https://onco.cc/drugs/daraxonrasib/)
- companies: [Revolution Medicines](https://onco.cc/companies/revolution-medicines/)

---
JSON: https://onco.cc/api/v1/entities/nct07252232.json